Aptevo Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APVO Nasdaq 2830 aptevotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptevo Therapeutics Inc.

Aptevo announces addition of preclinical candidate APVO455 to portfolio - Jun 21st, 2025 7:00 am
Aptevo Therapeutics Launches $8 Million Offering - Jun 18th, 2025 9:35 am
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Jun 18th, 2025 8:52 am
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML - Jun 18th, 2025 6:01 am
Aptevo Participating in the BIO International Convention - Jun 13th, 2025 6:05 am
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - May 22nd, 2025 6:05 am
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - May 15th, 2025 6:05 am
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - May 8th, 2025 6:45 am
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Apr 22nd, 2025 2:05 pm
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Apr 21st, 2025 12:40 pm
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Apr 4th, 2025 2:05 pm
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Apr 3rd, 2025 6:50 am
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment - Mar 20th, 2025 12:26 pm
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment - Mar 20th, 2025 6:35 am
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy - Mar 18th, 2025 6:05 am
Aptevo to Participate in March Conferences - Mar 6th, 2025 6:00 am
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Feb 15th, 2025 4:59 pm
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - Feb 14th, 2025 6:05 am
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - Jan 15th, 2025 6:00 am
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Dec 12th, 2024 10:50 am